Analysts Set Expectations for Delcath Systems Q1 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Delcath Systems in a report issued on Friday, May 23rd. HC Wainwright analyst S. Ramakanth forecasts that the company will earn $0.13 per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.25 EPS and Q4 2026 earnings at $0.34 EPS.

Delcath Systems (NASDAQ:DCTH) last announced its earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). The business had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%.

Separately, Wall Street Zen raised shares of Delcath Systems from a “buy” rating to a “strong-buy” rating in a report on Saturday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Delcath Systems has a consensus rating of “Buy” and a consensus price target of $24.00.

Delcath Systems Trading Down 0.2%

Shares of Delcath Systems stock opened at $16.11 on Monday. The business’s fifty day simple moving average is $13.05 and its 200 day simple moving average is $12.99. The firm has a market capitalization of $561.05 million, a P/E ratio of -11.93 and a beta of 0.72. Delcath Systems has a 12 month low of $6.33 and a 12 month high of $18.23.

Hedge Funds Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently modified their holdings of the company. Jefferies Financial Group Inc. purchased a new position in shares of Delcath Systems in the 4th quarter worth about $251,000. Principal Financial Group Inc. boosted its holdings in shares of Delcath Systems by 28.8% in the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock worth $1,387,000 after purchasing an additional 25,736 shares in the last quarter. Baader Bank Aktiengesellschaft purchased a new position in shares of Delcath Systems in the 4th quarter worth about $204,000. Private Advisor Group LLC purchased a new position in shares of Delcath Systems in the 4th quarter worth about $153,000. Finally, Jane Street Group LLC boosted its holdings in shares of Delcath Systems by 1,364.6% in the 4th quarter. Jane Street Group LLC now owns 178,797 shares of the company’s stock worth $2,153,000 after purchasing an additional 166,589 shares in the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.